Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 205,000 shares, effective March 2, 2026.

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 205,000 shares, effective March 2, 2026.

The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $24.02, equal to the last reported Nasdaq sale price on March 2, 2026.

Argus Mar 4 session

+3.88% close to close Open Argus

Details

News Market Reaction – OLMA

In the Mar 4 session, OLMA gained 3.88%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity compensation: inducement stock options for four new employe...

Analysis

This announcement details routine equity compensation: inducement stock options for four new employees covering 205,000 shares, vesting over four years with a 10-year term and a $24.02 exercise price. Similar grants in early 2026 also followed Nasdaq Listing Rule 5635(c)(4). In context with recent insider filings and board-approved plans, investors may focus on how cumulative option awards, vesting structures, and insider ownership trends evolve alongside future clinical, operational, or financing updates.

Key Figures

Inducement options: 205,000 shares Exercise price: $24.02 per share Option term: 10 years +5 more

Inducement options

205,000 shares

Aggregate stock options granted to four new employees

Exercise price

$24.02 per share

Equal to last reported Nasdaq sale price on March 2, 2026

Option term

10 years

Contractual life of the inducement stock options

Vesting period

4 years

Total vesting period for the stock options

Cliff vesting

25%

Portion vesting on first anniversary of vesting commencement date

Monthly installments

36 installments

Remaining vesting in equal monthly tranches over following three years

Current share price

$23.43

Pre-news price vs. $24.02 inducement option exercise price

Inducement employees

4 employees

Number of new employees receiving inducement grants

Historical Context

5 past events · Latest: Feb 19

5 events

1. Feb 19

   Conference presentation

   24h Move

   +1.1%

   Announcement of CEO presentation at TD Cowen health care conference.

2. Feb 04

   Investor conferences

   24h Move

   -5.0%

   Planned participation in multiple February 2026 investor conferences.

3. Feb 03

   Inducement grants

   24h Move

   +0.8%

   Inducement stock options for two new employees under 2022 Inducement Plan.

4. Jan 30

   Executive departure

   24h Move

   -0.3%

   Departure of Chief Operating and Financial Officer and interim finance transition.

5. Jan 05

   Inducement grants

   24h Move

   -0.2%

   Inducement options for new employees with four-year vesting and 10-year term.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), stock options, exercise price, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted under the Company's 2022 Inducement Plan ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"granted stock options to four new employees to purchase an aggregate of 205,000 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The stock options have a 10-year term and an exercise price of $24.02 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock options vest over four years, with 25 percent vesting on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $24.02 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on March 2, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Olema Oncology (OLMA) report on March 3, 2026 about inducement stock options?

Olema granted inducement options for an aggregate of 205,000 shares to four new employees. According to the company, the awards were effective March 2, 2026 and approved under its 2022 Inducement Plan per Nasdaq rule 5635(c)(4).

What are the vesting terms for the OLMA inducement stock options granted March 2, 2026?

The options vest over four years: 25% after one year, then monthly for three years. According to the company, continued employment through each vesting date is required for vesting.

What exercise price and term apply to the OLMA options granted in March 2026?

The options carry a $24.02 exercise price and a 10-year term. According to the company, $24.02 equals the last reported Nasdaq sale price on March 2, 2026.

How many employees received inducement grants in Olema Oncology's March 2026 filing (OLMA)?

Four new employees received inducement stock options totaling 205,000 shares. According to the company, the Compensation Committee approved the awards under the 2022 Inducement Plan.

Why did Olema Oncology (OLMA) issue inducement grants under Nasdaq Rule 5635(c)(4)?

Olema issued the awards as inducements material to new employees entering employment. According to the company, this was done in accordance with Nasdaq Listing Rule 5635(c)(4).

Do Olema's (OLMA) March 2026 inducement options affect shareholder dilution immediately?

The grants create potential future dilution if exercised, but no immediate dilution occurs until exercise. According to the company, the options are subject to the terms of the 2022 Inducement Plan.